[1]李 慧,胡云龙,朱士茂,等.TLR7激动剂作为狂犬病疫苗佐剂免疫效果的研究[J].中国预防兽医学报,2018,(06):523-527.[doi:0.3969/j.issn.1008-0589.201707015]
 LI Hui,HU Yun-long,ZHU Shi-mao,et al.The effect of TLR7 agonist as adjuvant in rabies vaccine[J].Chinese journal of preventive veterinary medicine,2018,(06):523-527.[doi:0.3969/j.issn.1008-0589.201707015]
点击复制

TLR7激动剂作为狂犬病疫苗佐剂免疫效果的研究()
分享到:

《中国预防兽医学报》[ISSN:1008-0589/CN:23-1417/S]

卷:
期数:
2018年06
页码:
523-527
栏目:
免疫学
出版日期:
2018-06-20

文章信息/Info

Title:
The effect of TLR7 agonist as adjuvant in rabies vaccine
文章编号:
1008-0589(2018)6-0523-05
作者:
 

李 慧1胡云龙2朱士茂1梁琳琳1刘永娣1罗 姗1郭采平1*靳广毅2*

 (1. 深圳市卫光生物制品股份有限公司,广东 深圳 518107;2. 深圳大学 医学院药学系,广东 深圳 518060)
Author(s):
 

LI Hui1 HU Yun-long2 ZHU Shi-mao1 LIANG Lin-lin1 LIU Yong-di1 LUO Shan1 GUO Cai-ping1* JING Guang-yi2*

 (1. Shenzhen Weiguang Biological Products Co., Ltd,  Shenzhen 518107, China;
2. Department of Pharmacy, School of Medicine, Shenzhen University,  Shenzhen 518060, China)
关键词:
TLR7激动剂狂犬病疫苗佐剂细胞因子中和抗体
Keywords:
 TLR7 agonist  rabies vaccine  adjuvant  cytokine  neutralizing antibody
分类号:
S852.65
DOI:
0.3969/j.issn.1008-0589.201707015
文献标志码:
A
摘要:
为提高狂犬病疫苗对机体的保护效果,本研究将不同浓度的Toll样受体7小分子激动剂(T7)作为佐剂加入到rabies vaccine中记为rabies vaccine+T7,分别将其与小鼠脾淋巴细胞一起培养,检测不同T7浓度对其细胞因子IFN-γ和IL-12的刺激,筛选适合的T7浓度;制备该浓度的rabies vaccine+T7溶液,通过对小鼠细胞免疫能力、中和抗体水平以及保护效果等方面评价T7对rabies vaccine的免疫佐剂效应,并以含铝佐剂的rabies vaccine (rabies vaccine+Al)为对照。结果显示,5.6 μmol/L~11.3 μmol/L的T7在体外可诱导良好的IFN-γ和IL-12反应;在体内,rabies vaccine+T7免疫小鼠诱生的特异性IFN-γ斑点形成细胞(SFC)数均高于其它组,产生中和抗体水平的速度比rabies vaccine+Al组快,保护效果与rabies vaccine+Al组相当。本研究结果表明T7作为佐剂能在一定程度上提高rabies vaccine的效果,有望开发为新型人用rabies vaccine的佐剂。
  
Abstract:
To improve the protective effect of rabies vaccine, different concentrations of toll-like receptors 7 agonist (T7) was added in the rabies vaccine (rabies vaccine+T7) as adjuvant, and cultivated with mice spleen lymphocytes. Then the cytokines IFN-γ and IL-12 were detected to evaluate the stimulating effect of T7. Mice were injected with the optimal concentration of rabies vaccine+T7, and the cellular immunity, neutralizing antibody level and protective effect were detected to examine immune adjuvant effect of T7 for rabies vaccine, with aluminium adjuvant (rabies vaccine+Al) as control. The results showed that T7 at the concentrations from 5.6 to 11.3μmol/L was able to efficiently induce IFN-γ and IL-12 reaction in vitro. In vivo, the rabies vaccine+T7 group induced more specific IFN-γ spot formation cell (SFC) than that in other group, showed a faster speed in inducing neutralizing antibodies and similar protective effect as compared with rabies vaccine+Al group. These results demonstrate that T7 has the capability to improve the effect of rabies vaccine in certain extent and is a promising candidate to be used as a new adjuvant of rabies vaccine for human beings.

参考文献/References:

[1]朱士茂,李慧,王春华,等. 狂犬病病毒及其与宿主之间的相互作用[J]. 中国预防兽医学报,2015,37(06):486-490.
[2]李娜,周伟芳,刘慧敏,等. 疫苗佐剂的研究现状和发展趋势[J]. 中国预防兽医学报,2013,35(1):81-86.
[3]Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity [J]. Nat Immunol, 2001, 2(8): 675-680.
[4]Akira S, Takeda K. Toll-like receptor signalling [J]. Nat Rev Immunol, 2004, 4(7): 499-511.
[5]Aderem A, Ulevitch R J. Toll-like receptors in the induction of the innate immune response[J]. Nature, 2000, 406(6797): 782-787.
[6]Carty M, Goodbody R, Schroder M, et al. The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling[J]. Nat Immunol, 2006, 7(10): 1074-1081.
[7]Lund J M, Alexopoulou L, Sato A, et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7[J]. PNAS, 2004, 101(15): 5598-5603.
[8]Maisonneuve C, Bertholet S, Philpott D J, et al. Unleashing the potential of NOD-and Toll-like agonists as vaccine adjuvants [J].PNAS, 2014, 111(34): 12294-12299.
[9]Homhuan A. Maturation of dendritic cells induced by nano-liposomes containing imiquimod [J]. Asian Biomed, 2008, 2(3): 233-239.
[10]Adams S, O’Neill D W, Nonaka D, et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant [J]. J Immunol, 2008, 181(1): 776-784.
[11]Huang Sheng-hai, Wei Wei, Yun Yun. Upregulation of TLR7 and TLR3 gene expression in thelung of respiratory syncytial virus infected mice [J]. Acta Microbiol Sin, 2009, 49(2): 239-245.
[12]陈婷婷,胡云龙,刘兵,等. Toll样受体7小分子激动剂偶联流感病毒灭活疫苗的研究[J]. 中国医药导报,2016,13(9):26-30.
[13]李渊,孙红祥. 不同类型免疫佐剂的作用比较[J]. 浙江畜牧兽医,2003,(5):16-18.
[14]Schijns V E, Lavelle E C. Trends in vaccine adjuvants [J]. Expert Rev Vaccines, 2011, 10(4): 539-550.
[15]Gupta R K, Relyveld E H, Lindblad E B, et al. Adjuvants - a balance between toxicity and adjuvanticity [J]. Vaccine, 1993, 11(3): 293-306.
                                                (本文编辑:李 娜)

更新日期/Last Update: 2018-07-12